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ABSTRACT
Docosahexaenoic acid (DHA), a ω-3 polyunsaturated fatty acid found in fish oil, is 
a multi-target agent and exerts anti-inflammatory and anticancer activities alone or in 
combination with chemotherapies. Combinatorial anticancer therapies, which induce 
immunogenic apoptosis, autophagy and STAT3 inhibition have been proposed for long-
term therapeutic success. Here, we found that DHA promoted immunogenic apoptosis 
in multiple myeloma (MM) cells, with no toxicity on PBMCs and DCs. Immunogenic 
apoptosis was shown by the emission of specific DAMPs (CRT, HSP90, HMGB1) by 
apoptotic MM cells and the activation of their pro-apoptotic autophagy. Moreover, 
immunogenic apoptosis was directly shown by the activation of DCs by DHA-induced 
apoptotic MM cells. Furthermore, we provided the first evidence that DHA activated 
autophagy in PBMCs and DCs, thus potentially acting as immune stimulator and 
enhancing processing and presentation of tumor antigens by DCs. Finally, we found 
that DHA inhibited STAT3 in MM cells. STAT3 pathway, essential for MM survival, 
contributed to cancer cell apoptosis by DHA. We also found that DHA inhibited STAT3 
in blood immune cells and counteracted STAT3 activation by tumor cell-released 
factors in PBMCs and DCs, suggesting the potential enhancement of the anti-tumor 
function of multiple immune cells and, in particular, that of DCs. 
INTRODUCTION
Docosahexaenoic acid (DHA; 22:6) is a long chain 
ω-3 polyunsaturated fatty acid (PUFA) primarily found in 
fish oil, that has been shown to have many health benefits 
in chronic diseases, such as inflammation-mediated 
diseases and cancer [1, 2]. Indeed, DHA can exert anti-
cancer activity towards several established solid and 
hematologic tumors [3-5]. In addition, DHA has been 
proposed as a non-toxic adjuvant to improve efficacy 
of conventional cancer therapies, since it can enhance 
the antitumor activity of chemotherapeutics, especially 
towards drug resistant cells, with no adverse effects 
[6-9]. The mechanisms underlying the anti-neoplastic 
effects of DHA are still unclear and need to be elucidated. 
Accumulating evidence indicates that DHA exhibits 
multiple mechanisms of action, including the in vitro and 
in vivo down-modulation of cancer cell proliferation and 
survival, invasiveness and metastasis, angiogenesis and 
inflammation [2, 5, 10-15]. It has been well documented 
that DHA represents a multi-target anticancer agent, since 
cell membrane enrichment with DHA induces changes 
in the distribution and function of several molecules, 
including key signaling mediators of cell survival and 
death [2, 5]. All these considerations greatly support 
investigations to further analyze and clarify the anti-
cancer effects of DHA, to assess its potential use in cancer 
therapy either alone [2-5] or in combinatorial strategies [6-
9] to improve the efficacy and tolerability of conventional 
anticancer treatments. 
Multiple Myeloma (MM) is a haematologic cancer 
of plasma cells infiltrating the bone marrow, where cancer 
cells, influenced by the microenvironment, become 
resistant to most drugs and apoptotic signals. MM cells are 
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characterized by the release of high levels of cytokines, 
which maintain cell autonomous proliferation/survival as 
well as suppress the immune response [16-18]. Indeed, 
the growth of MM, as of other tumors, is mainly due 
to the effect of tumor-released factors and relays on the 
constitutive activation of several pro-survival pathways 
including STAT3 [16, 19]. STAT3 constitutive activation 
in MM cells also confers them drug resistance [19-21]. 
In addition, STAT3, beyond its oncogenic role at the 
tumor cell level, has potent immunosuppressive effects 
in the tumor microenvironment, affecting the function 
of multiple lymphoid and myeloid cell types including 
dendritic cells (DCs) [22]. Indeed, in MM patients, tumor-
released suppressive factors (such as TGF-β, IL-10, IL-6 
and VEGF) can abrogate DC function, by activation of 
STAT3 [23-25].
DCs are at the center of the immune system owing 
to their ability to induce tumor-specific effector T cells, 
that can reduce the tumor mass and induce immunological 
memory to control tumor relapse, thus leading to long-
term survival [26]. Therefore, DCs represent an essential 
target in efforts to generate therapeutic immunity against 
cancer, especially during chemotherapy [26, 27]. The 
capability to stimulate protective anticancer immune 
responses by DCs depends on multiple conditions and 
multiple strategies have been proposed. One of the 
strategies is the so-called immunogenic chemotherapy, 
based on the capability of some chemotherapeutic agents 
to promote an immunogenic cancer cell apoptosis [27-29]. 
This means that a chemotherapeutic agent simultaneously 
induces cancer cell apoptosis and autophagy, where dying 
cancer cells emit a spatiotemporal-defined combination 
of specific damage-associated-molecular-patterns 
(DAMPs), that, loaded together with multiple tumor 
antigens in intact autophagosomes, are taken up by DCs, 
inducing their maturation, activation and antigen cross-
presentation, thus leading to the stimulation of an effective 
anti-tumor T cell response [27-29]. In addition, new 
studies have proposed that, together with immunogenic 
chemotherapeutics, autophagy enhancers should expand 
the pharmacological arsenal and augment the efficacy 
of cancer immunotherapy [30]. Indeed, autophagy 
enhancers affect cancer by attenuating tumor-promoting 
inflammation and stimulating antitumor immunity [30]. In 
particular, autophagy in DCs increases the processing and 
presentation of tumor antigens by both MHC class II and I 
molecules, thereby stimulating anti-tumor T cell response 
[30]. Finally, for all the reasons mentioned before, another 
promising therapeutic strategy for MM, and for other 
cancers as well, consists in STAT3 targeting [21, 31]. In 
fact, pharmacologic inhibitors of STAT3 pathway on the 
one hand affect cancer cell survival, suppressing tumor 
cell autonomous tumorigenesis [20, 21, 31] and on the 
other hand inhibit STAT3 inflammatory signaling in the 
hematopoietic system, eliciting multicomponent antitumor 
immune responses including those mediated by DCs [32-
34]. Indeed, STAT3 depletion in DCs improves cancer 
immunotherapy, by enhancing their ability to induce tumor 
antigen-specific T cells and promoting their resistance 
to cancer cell-derived inhibitory factors [35]. To notice, 
STAT3 inhibitors on tumor cells, used in combinatorial 
therapy with immunogenic chemotherapeutics such as 
anthracyclines, improve the outcome of immunogenic 
chemotherapy by stimulating the type-1 interferon 
production by cancer cells [36]. 
In this study, we investigated the promotion of cell 
death, the activation of autophagy and the inhibition of 
STAT3 by DHA in MM cells as well as in peripheral blood 
mononuclear cells (PBMCs) and DCs. In particular, we 
explored whether DHA promoted immunogenic apoptosis 
in MM cells, first analyzing its capability to trigger the 
emission of specific DAMPs by apoptotic cancer cells; 
then examining its capability to enhance autophagy 
in MM cells and the role of autophagy in cell viability. 
Lastly, we directly verified the immunogenicity of cell 
death induced by DHA by investigating whether MM 
cells undergoing DHA-mediated apoptosis were capable 
of activating DCs; we compared this effect to that obtained 
by using lipopolysaccharide (LPS), the classical DC 
activator. We also investigated the capability of DHA to 
activate autophagy in immune cells, such as PBMCs and 
DCs. Finally, we examined whether DHA was capable to 
inhibit STAT3 activation in MM cells, PBMCs and DCs. 
On this last point, we evaluated the capability of DHA 
to counteract STAT3 activation triggered by tumor cell-
released factors in both PBMCs and DCs.
RESULTS
DHA induces apoptosis in MM cells with no 
cytotoxic effects on PBMCs 
To investigate the promotion of cell death by DHA 
in human MM cells, we first analyzed the induction of 
cytotoxicity by DHA in MM cells vs normal PBMCs. To 
this purpose, two MM cell lines, RPMI-8226 and OPM-2, 
as well as PBMCs from two healthy donors were cultured 
in the presence of increasing doses of DHA (50-200 μM) 
for different time periods (24, 48 and 72 hours) and the 
effect of DHA on cell viability was determined by the 
trypan-blue exclusion assay. As shown in Figure 1A, 
DHA treatment resulted in a dose- and time-dependent 
cytotoxicity in both MM cell lines, whereas it did not 
affect the viability of normal PBMCs. 
To characterize the cell death induced by DHA in 
MM cells, we examined the occurrence of apoptosis by 
immunofluorescence, using the phosphatidylserine (PS)-
binding annexin V (AV) and the vital dye propidium 
iodide (PI), in RPMI-8226 and OPM-2 cells cultured in 
the presence of increasing doses of DHA (50-200 μM) 
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for 24 and 48 hours. As shown in Figure 1B, apoptotic 
cell death occurred in both MM cell lines and took place 
in a dose- and time-dependent manner. To confirm tumor 
cell death by apoptosis, MM cells were treated with 100 
μM DHA for 24 hours in the presence or in the absence 
of z-VAD pan-caspase inhibitor. As shown in Figure 1C, 
z-VAD inhibited apoptosis mediated by DHA in both cell 
lines. These results showed that DHA induced apoptotic 
cell death in MM cells, whereas it did not affect the 
viability of normal PBMCs.
DHA promotes immunogenic apoptosis in MM 
cells
Apoptosis can be immunogenic or tolerogenic, 
depending on its ability to trigger the emission by 
apoptotic cancer cells of a spatiotemporally-defined 
combination of DAMPs, which are able to stimulate 
antitumor immune responses through antigen presenting 
cells (APCs) such as DCs [27, 28, 37, 38]. Distinctive 
features of immunogenic apoptosis include the cell surface 
exposure of calreticulin (CRT) [39] and/or HSP90 [40] in 
pre- or early-apoptotic stages, as well as the release of 
non-histone chromatin protein high mobility group box 1 
(HMGB1) by cancer cells in late-apoptosis or secondary 
necrosis [41]. Therefore, we investigated whether 
DHA-mediated apoptosis in MM cells had the ability to 
trigger the emission of the specific DAMPs in the proper 
spatiotemporally-defined combination. We found that 
both CRT and HSP90 were exposed on the cell surface 
of RPMI-8226 and OPM-2 cells treated with DHA for 3 
and 6 hours, respectively (Figure 2A). Moreover, HMGB1 
was released in the conditioned medium by both RPMI-
8226 (left panel) and OPM-2 (right panel) cells at late 
apoptotic stages (Figure 2B). All together, these results 
suggested that apoptosis mediated by DHA in MM cells 
was immunogenic. 
DHA activates autophagy in MM cells, PBMCs 
and DCs
Another required feature of immunogenic apoptosis 
includes the capability of chemotherapeutics to activate 
autophagy in cancer cells [29, 30]. Therefore, we explored 
Figure 1: DHA induces apoptosis in MM cells and does not affect PBMC viability. A. DHA decreases viability of MM cell 
lines in a dose- and time-dependent manner, whereas it does not affect the survival of PBMCs derived from healthy donors. RPMI-8226, 
OPM-2 and PBMCs were cultured with vehicle (Ctrl) or DHA (µM) and their viability evaluated by trypan blue exclusion assay; mean 
of the percentage of cell surviaval plus SD of three independent experiments is indicated; B. RPMI-8226 and OPM-2 were cultured 
with vehicle (Ctrl) or DHA (µM) and apoptosis was assessed by Annexin V-FITC (AV) and propidium iodide (PI) cell staining and flow 
cytofluorimetry; representative experiments out of three; C. RPMI-8226 and OPM-2 were cultured with vehicle (Ctrl) or 100 μM DHA 
for 24 hours in the absence or presence of z-VAD-FMK (50 μM) and analyzed for apoptosis by AV and PI cell staining; representative 
experiments out of three.
Genes & Cancer429www.impactjournals.com/Genes&Cancer
the activation of autophagy in MM cells by DHA and its 
role in cancer cell viability. To this purpose, the main 
autophagic markers such as LC3I/II and p62 [42] were 
evaluated by Western blot analysis. As shown in Figure 
3A-B, LC3II formation increased both in RPMI-8226 
and in OPM-2 cells cultured with DHA (100 μM) for 24 
hours and accumulated in the presence of Bafilomycin 
(Baf), an inhibitor of ATP vacuolase that, by blocking 
LC3II degradation, allows to evaluate LC3 formation 
and consequently the completeness of the autophagic 
flux [42]. Conversely, p62 decreased (Figure 3A-
B), further indicating that DHA was able to activate 
a complete autophagy in MM cells. Next, the role of 
autophagy activated by DHA in MM cell viability was 
investigated by the administration of the autophagic 
inhibitor 3-methyladenine (3-MA). As shown in Figure 
3C (left panel), the viability of RPMI-8226 cells was 
increased when 3-MA was applied. According to this 
observation, we also found that 3-MA partially decreased 
the percentage sub-G1 events, indicative of apoptotic 
nuclei, while increased the percentage of cells in the G1 
phase (Figure 3C, right panel). These results implied that 
autophagy by DHA played a pro-apoptotic role in MM 
cells and that contributed to apoptotic cell death mediated 
by DHA.
Then, we investigated the activation of autophagy 
by DHA in immune cells. As shown in Figure 4, increased 
LC3II formation and decreased p62 appeared in both 
PBMCs (panel A) and DCs (panel B) following their 
treatment with 100 μM DHA for 24 hours. Moreover, it is 
worth noting that, according to the results shown in Figure 
1A, DHA did not induce toxic effects in either PBMCs 
(panel A) or DCs (panel B) (Figure 4). These findings 
indicate that DHA is an enhancer of autophagy in immune 
Figure 2: DHA triggers the emission of immunogenic DAMPs by MM cells. A. RPMI-8226 and OPM-2 were cultured with 
vehicle (Ctrl) or 100 μM DHA for 3 and 6 hours, respectively; cell surface immunofluorescence staining using anti-CRT, anti-HSP90 or 
isotype control antibodies was analyzed by flow cytofluorimetry, while gating on the viable population and excluding dead cells stained 
with PI; numbers indicate the ratio of the mean fluorescence intensity (MFI) of DHA treated cells/MFI of control cells. B. RPMI-8226 and 
OPM-2 were cultured with vehicle (Ctrl) or 100 μM DHA for the indicated times; then, tumor cell conditioned media were collected and 
the presence of HMGB1 was analyzed by Western blot; β-actin was used as intracellular protein control and Ponceau staining as loading 
control. Representative experiments out of three.
Genes & Cancer430www.impactjournals.com/Genes&Cancer
cells as well, potentially decreasing their inflammatory 
activity and enhancing their immune response against 
tumor antigens [30]. 
DHA-triggered immunogenic apoptosis in MM 
cells activates DCs
Since all the present results indicated that DHA-
mediated apoptosis in MM cells had the features of 
immunogenic apoptosis, we investigated whether 
cancer cells undergoing apoptosis by DHA were able to 
activate DCs. To this purpose, immature DCs (iDCs), 
generated from human peripheral blood derived CD14+ 
monocytes cultured with human recombinant granulocyte-
macrophage colony stimulating factor (GM-CSF) and 
interleukin-4 (IL-4) for 6 days, were co-cultured with 
DHA-induced apoptotic RPMI-8226 cells for 24 hours and 
the expression of DC activation markers was analyzed. As 
positive control of DC activation, iDCs were treated with 
LPS (100 ng/ml) for the same time (Figure 5A). As shown 
in Figure 5B, DHA up-regulated the expression of DC 
differentiation and activation markers CD83 and CD86, 
respectively, as evidenced by flow cytometric analysis. 
DHA inhibits STAT3 activation in MM cells, 
PBMCs and DCs
The inhibition of the STAT3 pathway in both 
cancer and immune cells (particularly myeloid 
populations) constitutes an important target for cancer 
therapy, including MM therapy [19-22, 24, 25, 31-35]. 
Therefore, we investigated whether DHA was capable 
to inhibit STAT3 in MM cells as well as in PBMCs and 
DCs. To this purpose, both RPMI-8226 and OPM-2 
cells were treated with 100 μM DHA for 24 hours and 
phosphorylated STAT3 (p-STAT3) was evaluated by 
Western blot analysis. As shown in Figure 6A left panels, 
DHA strongly suppressed STAT3 tyrosine phosphorylation 
in both MM cell lines. Moreover, DHA-induced STAT3 
Figure 3: DHA enhances autophagy in MM cells, 
which contributes to DHA-induced cell death. RPMI-
8226 (A) and OPM-2 (B) were cultured with vehicle (Ctrl) or 
100 μM DHA for 24 hours in the presence or in the absence of 
Bafilomycin (Baf) and the expression of the autophagic markers 
such as LC3I/II and p62 was analyzed by Western blot; β-actin 
was included as control; numbers indicate band intensities (b.i.) 
= band volume/area x mean pixel intensity, normalized for 
β-actin and quantified using Quantity One 1-D analysis software; 
C. RPMI-8226 cells were cultured for 24 hours with vehicle 
(Ctrl) or 100 μM DHA in presence or absence of 3-MA (0.3 
mM) and their viability assessed by trypan blue exclusion assay 
(left panel) and cytofluorimetry cell cycle analysis of sub-G1 
events, representing apoptotic cells (right panel). Representative 
experiments out of three.
Figure 4: DHA enhances autophagy in PBMCs and 
DCs. PBMCs (A) and DCs (B) derived from healthy donors 
were cultured with vehicle (Ctrl) or 100 μM DHA for 24 hours 
and the expression of the autophagic markers LC3I/II and p62 
was analyzed by Western blot; β-actin was included as control; 
numbers indicate band intensities (b.i.) = band volume/area x 
mean pixel intensity, normalized for β-actin and quantified using 
Quantity One 1-D analysis software; the viability of PBMCs 
(A) and DCs (B) was assessed by trypan blue exclusion assay. 
Representative experiment out of three.
Genes & Cancer431www.impactjournals.com/Genes&Cancer
de-phosphorylation was reduced by the broad-acting 
phosphatase inhibitor sodium orthovanadate (OV) 
[43] (Figure 6A, left panels), suggesting that tyrosine 
phosphatases were involved in DHA-mediated STAT3 de-
phosphorylation. Then, we investigated the possible role 
of STAT3 in DHA-mediated cytotoxicity in MM cells. 
As shown in Figure 6A, right panels, we found that OV 
treatment reduced the cytotoxicity mediated by DHA both 
in RPMI-8226 and OPM-2 cells, suggesting that STAT3 
inhibition was involved in DHA-mediated cell death. 
Next, to investigate the inhibition of the STAT3 
pathway in immune cells, PBMCs and DCs derived 
from healthy donors were treated with 100 μM DHA for 
24 hours in the absence or presence of MM cell-derived 
conditioned medium and STAT3 phosphorylation was 
evaluated by Western blot analysis. As shown in Figure 
6B-C (left panels), DHA strongly suppressed both 
constitutive and tumor cell conditioned medium (TCCM)-
induced activation of STAT3 in both PBMCs and DCs, 
indicating that DHA can inhibit STAT3 signaling in 
immune cells and has the potential to counteract STAT3 
activation induced by MM cell-released factors. Finally, 
according to the results obtained in tumor cells, DHA-
induced STAT3 de-phosphorylation was reduced by 
OV (Figure 6B-C, left panels), suggesting a role for 
tyrosine phosphatases in DHA-mediated STAT3 de-
phosphorylation in immune cells. Moreover, according to 
previous results (Figures 1A and 4), DHA treatment did 
not affect the viability of PBMCs and DCs (Figure 6 B-C, 
right panels). 
DISCUSSION 
Despite progress made in recent years in cancer 
chemotherapy, this therapeutic strategy alone has not 
provided satisfactory clinical results in terms of the 
long-term survival of patients, mainly related to the 
development of drug resistance by cancer cells, toxicity 
towards normal cells and impaired immunity [27, 44]. 
Evidence exists that the host immune system plays a major 
role in long-term therapeutic success and combinatorial 
multi-targeted strategies, where chemotherapeutic agents 
are combined with immunotherapies, are needed to 
completely eradicate cancer diseases [27, 44].
DHA represents one of the most promising natural 
products in the therapy of various human inflammation-
mediated diseases and cancer, being able to target multiple 
key molecules in different compartments of tumor and 
normal cells [1-5, 14, 15]. Moreover, the well documented 
capability of DHA to induce selective cytotoxicity against 
several types of solid and hematologic cancer cells in 
vitro and in vivo without exerting toxic effects in the 
corresponding normal cell types [2, 5, 45-49] makes DHA 
a potentially ideal anticancer agent.
In this study, we found that DHA induced 
immunogenic apoptosis in MM cells, while, according 
to the literature [5, 45], did not induce cytotoxicity in 
normal PBMCs and DCs. The immunogenicity of cell 
death induced by DHA in MM cells was first indicated 
by the finding that MM apoptosis was associated with the 
correct spatiotemporally-defined cell surface exposure 
not only of CRT, as we showed in an earlier study on 
other tumor models [50], but also of HSP90, followed 
Figure 5: DHA-triggered immunogenic apoptosis in MM cells activates DCs. Immature DCs (iDCs), generated from PBMC-
derived CD14+ monocytes cultured with GM-CSF and IL-4 for 6 days, were co-cultured with vehicle- (Ctrl) or DHA-treated RPMI-8226 
cells for 24 hours and the expression of DC differentiation (CD83) and activation (CD86) markers was analyzed by immunofluorescence 
and flow cytometry (B). As positive control of DC activation, cells were treated with LPS (100 ng/ml) for the same time (A). Representative 
experiment out of three.
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by the extra-cellular release of HMGB1, all specific 
DAMPs representing distinctive features of immunogenic 
apoptosis [27, 28, 38]. Then, we showed that DHA 
activated autophagy in MM cells. This is important, 
since autophagy, although dispensable for chemotherapy-
induced cell death, is required for its immunogenicity, 
as it enhances the release of specific DAMPs (including 
ATP, HMGB1, uric acid), allowing cancer cells to 
attract DCs and T lymphocytes into the tumor bed [27, 
30]. Noteworthy, autophagy in cancer cells can also 
indirectly promote “cross-presentation” of tumor antigens 
by facilitating antigen release from dying cells, thereby 
increasing extracellular antigen availability [30]. It has 
been recently shown that cancers, in which autophagy 
was upregulated, exhibit higher density of CD8+ T cells 
and lower number of Foxp3+ T regulatory cells (Treg) 
in the tumor bed [30, 51]. Moreover, we found that 
DHA-activated autophagy in MM cells amplified their 
apoptotic cell death, since the inhibition of autophagy 
by 3-MA increased cancer cell viability. Our findings are 
consistent with earlier studies demonstrating that DHA 
can simultaneously promote apoptosis and autophagy 
in different solid tumors in vitro and in vivo [52, 53]. 
Although the mechanism underlying DHA-activated 
autophagy has not yet been fully elucidated, it has been 
proposed to be dependent on the inhibition of mTOR (a 
negative regulator of autophagy initiation) by DHA, via 
AMPK activation and PI3K/Akt inhibition [53]. Finally, 
we directly showed the immunogenicity of DHA-mediated 
apoptosis by the capability of apoptotic MM cells to 
activate DCs. 
Next, we provided the first evidence that DHA was 
capable to activate autophagy in PBMCs and DCs, while 
did not affect their viability. This is an important point, 
since, in tumor bearing mice or cancer patients, tumor-
infiltrating APCs are often functionally compromised 
and APC autophagy needs to be stimulated to facilitate 
processing and cross-presentation of tumor antigens by 
MHC molecules, ensuring the generation of effective 
antitumor T cells [30]. Currently, autophagy is considered 
as an immune stimulator, which tunes down inflammation 
and boosts adaptive immunity against tumor progression 
[30].
Finally, we showed that DHA targeted STAT3 
Figure 6: DHA inhibits STAT3 pathway in MM cells, PBMCs and DCs. A. RPMI-8226 and OPM-2 were cultured with 
vehicle (Ctrl) or 100 μM DHA for 24 hours in the presence or absence of sodium orthovanadate (OV) (150 μM) and STAT3 tyrosine 
phosphorylation (p-STAT3) was evaluated by Western blot (left panels); total STAT3 and β-actin were included as control; numbers indicate 
band intensities (b.i.) = band volume/area x mean pixel intensity, normalized for β-actin and quantified using Quantity One 1-D analysis 
software; viability of MM cells was assessed by trypan blue exclusion assay (right panels); *p< 0.000; PBMCs from healthy donors (B) 
and iDCs (C), generated from PBMC-derived CD14+ monocytes cultured with GM-CSF and IL-4 for 6 days, were cultured with vehicle 
(Ctrl) or 100 μM DHA for 24 hours in the presence or absence of tumor cell conditioned medium (TCCM) or OV (150 μM), and evaluated 
for STAT3 tyrosine phosphorylation by Western blot (left panels); total STAT3 and β-actin were included as control; numbers indicate 
band intensities (b.i.) = band volume/area x mean pixel intensity, normalized for β-actin and quantified using Quantity One 1-D analysis 
software; the viability of PBMCs and DCs was assessed by trypan blue exclusion assay (right panels). Representative experiments out of 
three.
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signaling by strongly inhibiting STAT3 phosphorylation 
in tumor cells as well as in PBMCs and DCs. STAT3 
inhibition in cancer cells appeared to be involved in 
the apoptotic process promoted by DHA, as STAT3 de-
phosphorylation was associated with cancer cell death and 
treatment with a phosphatase inhibitor inhibited the cancer 
cell death. Our findings are consistent with previous data, 
showing the capability of DHA to inhibit STAT3 in other 
tumor cell models [54, 55]. Moreover, new data have 
shown that STAT3 inhibitors, in combinatorial therapy 
with anthracycline-based immunogenic chemotherapy, 
potentiated the immunogenic chemotherapy [32]. 
Noteworthy, the capability of DHA alone both to promote 
immunogenic apoptosis and to inhibit STAT3 in MM 
cells, makes this agent potentially more advantageous 
than conventional immunogenic chemotherapeutics. 
In addition, we found that DHA inhibited STAT3 in 
peripheral blood immune cells and, more importantly, 
has the potential to counteract STAT3 activation by tumor 
cell-released factors in PBMCs and DCs, with no toxic 
effects. Although STAT3 inhibitory activity by DHA 
has been previously reported in hepatocytes [56] and 
adipocytes [57] as a mechanism contributing to the anti-
inflammatory effect of DHA, the capability by DHA to 
induce STAT3 inhibition in immune cells, including DCs, 
has not been described before. Our findings, showing 
STAT3 inhibition in immune cells by DHA, might result 
in an enhancement of the antitumor response of multiple 
peripheral blood immune cell populations, especially 
that of DCs [22-25]. To the best of our knowledge, no or 
little studies have investigated the effect of DHA-based 
clinical trials in cancer patients on the anti-tumor immune 
response. Eltweri et al. [15], reviewing ω3-PUFAs-
based trials in the pre- and/or post-operative setting in 
gastrointestinal cancers, reported in several studies the 
reduction of inflammatory markers and the improvement 
of the immune function, such as an increased resistance to 
infectious diseases.
In conclusion, our findings, indicating that DHA 
promotes immunogenic apoptosis in MM cells with no 
toxicity on PBMCs and DCs, activates autophagy and 
inhibits STAT3 in MM cells as well as in PBMCs and DCs, 
strongly encourage the potential use of this multi-target 
agent in cancer therapy either alone or in combinatorial 
strategies, to potentiate conventional immunogenic or 
non-immunogenic chemotherapies. 
MATERIALS AND METHODS
Tumor Cells
The human MM cell lines RPMI-8226 and OPM-2 
were provided by P. Trivedi (“ La Sapienza” University of 
Rome, Italy). Cell lines were maintained at 37°C and 5% 
CO2 in RPMI 1640 (Sigma Aldrich) supplemented with 
10% FCS (Hyclone), 100 mg/ml streptomycin and 100 IU/
ml penicillin (EuroClone). All cell lines were mycoplasma 
free (EZ-PCR Mycoplasma test kit; Biological Industries). 
Peripheral Blood Mononuclear Cells (PBMCs) 
and Immature DC (iDC) generation 
Human PBMCs from healthy donors were isolated 
by Lymphoprep gradient centrifugation (Nycomed). 
Monocytes were isolated by immunomagnetic cell 
separation using anti-CD14-conjugated microbeads 
(Miltenyi Biotec, 1300-50-201). To induce the 
differentiation of iDCs, monocytes were cultured for 6 
days with human recombinant granulocyte-macrophage 
colony stimulating factor (GM-CSF) (50 ng/mL) (Milteny 
Biotec, 130-093-865) and interleukin-4 (IL-4) (20 ng/mL) 
(Miltenyi Biotec, 130-095-373), as previously described 
[58].
iDC/tumor cell co-cultures
iDCs were co-cultured with DHA-treated tumor 
cells for 24 hours, at a 1:2 iDC/tumor cell ratio, as 
previously described [58]. 
Drug treatment 
Cells were cultured with DHA (Sigma-Aldrich, 
D2534-100MG), dissolved in ethanol solution or with 
ethanol solution alone (Ctrl) at the indicated doses, for 
the indicated times. In some experiments, z-VAD-FMK 
pan-caspase inihibitor (50 μM) (Calciochem; 219011) 
or sodium orthovanadate (OV) (150 μM) (Sigma 
Aldrich, 450243) were added to the cell culture 30 
minutes before DHA (100 μM) treatment for 24 hours; 
in others, 3-methyladenine (3-MA) (0.3 mM) (Santa Cruz 
Biotechnology Inc., sc-205596) was added 6 hours after 
DHA (100 μM) treatment for 24 hours. For the autophagic 
investigation, MM cells were cultured with DHA (100 
μM) for 24 hours and then treated with Bafilomycin 
A1 (Baf) (20 nM) (Santa Cruz Biotechnology Inc., sc-
201550), an inhibitor of vacuolar-H+-ATPase, for the last 
2 hours. For DC activation, iDCs were cultured with LPS 
(100 ng/mL) for 24 hours.
Cell viability and Apoptosis assay 
After each chemical treatment, cell viability was 
assessed by the trypan blue dye exclusion assay. Live 
cells were counted by light microscopy using a Neubauer 
hemocytometer. Apoptosis was assessed by annexin 
V-FITC and propidium iodide staining, as previously 
described [59]. DNA fragmentation was quantified by flow 
cytometry of hypodiploic (sub-G1) DNA after cell fixation 
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and PI staining, as previously described [60].
Immunofluorescence and flow cytometric analysis 
Immunofluorescence was performed using 
antibodies against CRT (FMC75; MBL International 
SR601D MBL), HSP90 (AC88; StressGen ADI-SPA-
830-D), CD14 (Miltenyi Biotec, 130-080-701), CD1a 
(BD Biosciences Pharmingen, 555807), CD86 (Milteny 
Biotec, 130-094-878), CD83 (Miltenyi Biotec, 130-094-
181) or appropriate isotype control antibodies. Samples 
were analyzed by a FACSCalibur (Becton Dickinson) or 
EPICS XL (Beckman Coulter) flow cytometer. DCs were 
gated according to their FSC and SSC properties. At least 
5 x 103 events were acquired for each sample. 
Western blot analysis 
Cell lysates were prepared by a solution containing 
50 mM TRIS-HCl pH 7.6, 150 mM NaCl, 0.5% TRITON 
X-100, 0.5% Sodium deoxycolate, 0.1% SDS and the 
protease inhibitor mixture ‘‘Complete’’ (Roche Diagnostic 
GmbH). Proteins were separated by SDS-PAGE, blotted 
onto nitrocellulose (Whatman-Protan BA85) and 
incubated with appropriated primary antibodies specific 
for: STAT3 (BD Transduction Laboratories; 610189), 
phosphoSTAT3 (pY705) (BD Transduction Laboratories; 
612356), LC3 (Novus Biologicals, NB100-2220SS), 
p62 (BD Transduction Laboratories, 610832), HMGB1 
(Abcam, 18256) or β-actin Ac-40 (Sigma-Aldrich, 
A4700). The reaction was revealed by horseradish 
peroxidase (HRP)-coupled secondary reagents (Bio-
Rad) and developed by enhanced chemiluminescence 
(Amersham ECL Western Blotting Detection Reagent). 
Band intensities (b.i.) = band volume/area x mean pixel 
intensity, normalized for β-actin, were quantified using 
Quantity One 1-D analysis software (Bio-Rad). 
Statistics 
Student’s t test was used for all analyses; p < 
0.05 was considered significant. All experiments were 
performed at least three times.
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